Biochemical recurrence after radiotherapy has long been considered a possible indicator of long-term survival in patients with localized prostate cancer.
However, a new study led by UCLA researchers challenges this notion, asserting that biochemical recurrence is not a reliable surrogate endpoint for overall survival.
Study Overview
The study, published in the Journal of Clinical Oncology, involved data from 11 different studies and encompassed a total of 10,741 patients.
The researchers investigated whether biochemical recurrence could act as a reliable predictor for overall survival in patients undergoing radiation therapy for localized prostate cancer.
The evaluation was pivotal for the designing of clinical trials and for counseling patients on treatment options.
Key Findings
The study found that while biochemical recurrence was correlated with a higher risk of death, it did not reliably predict long-term overall survival.
According to the FDA’s definition, a surrogate endpoint should be a specific and early outcome that reliably forecasts long-term clinical outcomes, such as how a patient feels, functions, or survives. Biochemical recurrence failed to meet these criteria.
Dr. Amar Kishan, senior author of the study and an associate professor at the David Geffen School of Medicine at UCLA, stated that the lack of correlation could be due to many patients dying from causes unrelated to prostate cancer.
He also emphasized that the study focused on death as an endpoint, not quality of life.
Future Directions
Based on these findings, the researchers recommend that future clinical trials should not use biochemical recurrence as the primary measure for localized prostate cancer.
Instead, they suggest that metastasis-free survival is a more appropriate and reliable endpoint for these trials.
Conclusion
The UCLA-led study significantly impacts how we understand the progression and treatment of localized prostate cancer.
While biochemical recurrence remains important for understanding a patient’s condition, it may not be a reliable predictor of long-term survival.
This nuanced understanding could alter the design of future clinical trials and the way clinicians counsel their patients, potentially leading to more accurate and effective treatments.
By challenging a long-held assumption, this study opens new doors for research and provides valuable insights for the medical community in treating one of the most common cancers in men.
If you care about cancer, please read studies about new vaccines to prevent pancreatic cancer, and scientists find the cause of prostate cancer metastasis.
For more information about cancer, please see recent studies about an effective drug combo to treat liver cancer, and results showing this berry may protect you from cancer, diabetes, and obesity.
The study was published in the Journal of Clinical Oncology.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
